Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?
Reviewed 21 sourcesPublished by PepVault
Every GLP-1 label's breastfeeding line side by side, what milk studies measured for semaglutide and tirzepatide, why the pills differ, and ACOG's 2026 advice.

- Last reviewed
- Sources
- 21
- Questions
- 7
- Compounds
- 7
The short answer
In the US, the labels for the GLP-1 shots (Ozempic, Wegovy, Mounjaro, Zepbound) leave it to you and your prescriber to weigh breastfeeding's benefits against your need for the drug. In milk studies, injected semaglutide was undetectable and tirzepatide mostly so. The semaglutide tablets and Foundayo are not recommended, and ACOG advises against any GLP-1 with a preterm baby or newborn. European and UK advice is mostly stricter.
Evidence: US and European prescribing labels, one company lactation study for tirzepatide (11 women) and one for semaglutide tablets, one independent milk study of injected semaglutide (8 women), LactMed, and ACOG's 2026 practice advisory; no study has followed breastfed babies or milk supply over time, and the other GLP-1s have no human milk data.

What does each GLP-1 label say about breastfeeding?
Every US label has a section 8.2, Lactation. For the injections it ends on the same sentence: "The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need" for the drug and any possible effect on the baby1245. That is not a no. It hands the decision to you and your prescriber. Two pills are the exception, and they say so plainly. Here is each label as it stands on DailyMed on November 20, 2026:
| Medicine | Form | The label's line | Measured in human milk |
|---|---|---|---|
| Ozempic (semaglutide) | Weekly shot | Weigh the benefits of breastfeeding against the need for the drug1 | No human data; in rats, milk levels 3 to 12 times lower than the mother's blood1 |
| Wegovy shot (semaglutide) | Weekly shot | The same weighing; the label adds that the shot has no SNAC2 | No human data on the label2 |
| Wegovy tablets (semaglutide) | Daily pill | "Breastfeeding is not recommended"2 | Semaglutide below the lowest measurable level; SNAC found in milk2 |
| Rybelsus and Ozempic tablets (semaglutide) | Daily pill | "Breastfeeding is not recommended"3 | Semaglutide below the lowest measurable level; SNAC found in milk3 |
| Mounjaro and Zepbound (tirzepatide) | Weekly shot | The same weighing45 | Undetectable in 164 of 171 samples from 11 women45 |
| Saxenda and Victoza (liraglutide) | Daily shot | The same weighing67 | No human data; in rats, milk about half the mother's blood level67 |
| Trulicity (dulaglutide) | Weekly shot | The same weighing8 | No human data; not measured in animals either8 |
| Byetta (exenatide) | Twice-daily shot | The same weighing9 | No human data; in mice, milk up to 2.5% of the blood level9 |
| Foundayo (orforglipron) | Daily pill | "Not recommended for nursing women"10 | No human data; in rats, radio-labelled drug in milk at 3 times the blood level10 |
The rat, mouse and rabbit numbers are animal results. Two labels say outright that species differences in how milk is made leave their meaning for people unclear19.
PepVault keeps the date and amount of every dose you log, so when your prescriber or your baby's doctor asks when you last took it, or when a step-up began, the answer is on record. Log it in PepVault

How much semaglutide or tirzepatide gets into breast milk?
Very little, often nothing. Three measurements exist:
| Study | Who and how | What was found |
|---|---|---|
| Tirzepatide, Lilly's lactation study45 | 11 healthy women, one 5 mg shot, milk sampled for 28 days | None detectable in 164 of 171 samples (the test sees down to 4 ng/mL). The other 7 held less than 0.02% of the mother's dose in total; the last trace was on day 5 |
| Injected semaglutide, Diab 202411 | Milk from 8 women, taken 0, 12 and 24 hours after their weekly shot | None detected in any sample (the test sees down to 1.7 ng/mL). Worst-case relative infant dose: 1.26% |
| Semaglutide tablets, the label's lactation study23 | Women taking the tablet; the label gives no number | Semaglutide below the lowest level the test can count; SNAC and its breakdown products present |
The semaglutide study's worst case is a relative infant dose: the share of the mother's dose, per kilogram of body weight, a baby would get through milk if milk held the drug at the lowest level the test can count (5.7 ng/mL). Below 10% is the usual line for a medicine to count as compatible with breastfeeding, and 1.26% is well under it11. The study was small, and it measured milk, not babies.
The reason is size. These drugs are peptides, chains of amino acids, and big ones: semaglutide weighs 4,114 daltons, tirzepatide 4,814, exenatide 4,187 and liraglutide 3,751, and dulaglutide is joined to part of an antibody at about 63,00014689. Foundayo's orforglipron, an ordinary pill-sized molecule, weighs 90210. Molecules that big pass poorly into milk1415. What does get through is a protein in the baby's gut, which LactMed, the US National Library of Medicine's drugs-in-breastfeeding database, says is probably partly broken down there and poorly absorbed1314. For injected semaglutide, LactMed adds that these mothers' breastfed babies had no adverse effects12.
Why are the semaglutide tablets and Foundayo not recommended?
Not because of the drug in the milk. Semaglutide tablets carry SNAC (salcaprozate sodium), a helper that lets the peptide be absorbed in the stomach. Semaglutide itself was below the measurable level in milk, but SNAC and its breakdown products were present. The labels explain that the enzymes that clear SNAC may work more slowly in babies, so SNAC could build up in newborns and infants, and since semaglutide shots without SNAC exist, they say not to breastfeed on the tablets23. The Wegovy label makes the point itself: the shot "does not contain the SNAC metabolites"2.
Foundayo is a different kind of molecule. Orforglipron is not a peptide but a small molecule of 902 daltons, the size of an ordinary pill, and in rats, radio-labelled orforglipron reached milk at 3 times its blood level10. The label's reasoning is direct: "When a drug is present in animal milk, it is likely that the drug will be present in human milk", so it is "not recommended for nursing women"10. ACOG reaches the same place from a different side and advises people who breastfeed to avoid oral GLP-1s15.
What do ACOG and other health bodies say?
The same small studies are read in different ways. In October 2026 the American College of Obstetricians and Gynecologists (ACOG) published its advice on GLP-1s in pregnancy and lactation15. Europe and the UK are stricter than the US labels, with one exception:
| Who | What they say about breastfeeding |
|---|---|
| ACOG, US obstetricians (October 2026)15 | Shared decision-making on a postpartum plan that may include a GLP-1; if used, the baby's weight gain is watched closely with the baby's clinician; recommend against with preterm babies and "neonates" (in medicine, the first 28 days; ACOG gives no age); prefer shorter half-lives; avoid the oral forms |
| LactMed, US National Library of Medicine121314 | Semaglutide: only the injectable forms. Tirzepatide: "not a reason to discontinue breastfeeding", with caution for a newborn or preterm baby. Liraglutide: amounts in milk likely very low, same caution |
| European labels (EMA)161718 | Ozempic and Wegovy: "should not be used during breast-feeding". Mounjaro: tirzepatide "could be considered for use during breast-feeding" |
| MHRA, UK regulator (February 2026)19 | GLP-1 medicines "should not be taken by people who are breastfeeding", because there is not enough safety data |
None of these rests on a study of breastfed babies over months. A 2026 review of diabetes medicines in breastfeeding found that only 5 of 20 had any data on transfer into milk, semaglutide among them, and that 4.4% of guideline recommendations were based on clinical evidence20. So the advice is caution where the data are thinnest: the youngest and smallest babies, and the pills. Where you live decides which label you read, and your prescriber decides which applies to you.
Does a GLP-1 affect milk supply or the baby's weight?
No one has measured it. The US labels that address it say there are no data on the effect on milk production or on the breastfed baby1410. ACOG names the open question: a GLP-1 lowers your appetite, and eating too little could in theory change how much milk you make or what is in it in ways that hold back the baby's growth, and it asks for the baby's weight gain to be watched closely15. Europe's Mounjaro label says the same: whether lower food intake changes the milk's nutrient content is not known18.
Commonly reported: worry about supply in the first weeks on a dose, finding it hard to eat enough while nursing, and restarting after weaning or once the baby is on solid food.
PepVault's food log sets a daily protein target from your weight and counts each meal against it, so the days you ate too little show up before they add up. Track your food in PepVault
When to get help Call your baby's doctor if your baby feeds less, has fewer wet diapers or stops gaining weight, and call your own prescriber if you cannot keep food or fluids down.
Which GLP-1 clears fastest, and why does that matter?
A general rule for medicines while breastfeeding is to choose the one with the shorter half-life, the time the body takes to clear half of a dose, because a stop or a pause takes effect sooner. ACOG applies it to GLP-1s and names exenatide as the preferred choice if one is needed15, but FDA's Drugs@FDA database lists Byetta, Bydureon and the one generic exenatide as discontinued21. Among the GLP-1s still marketed in the US, liraglutide is the shortest-acting. From the labels:
| Drug (brand) | Half-life on the label | Given |
|---|---|---|
| Exenatide (Byetta, discontinued in the US) | 2.4 hours9 | Twice a day |
| Liraglutide (Saxenda, Victoza) | About 13 hours67 | Once a day |
| Orforglipron (Foundayo) | 29 to 49 hours10 | Once a day, by mouth |
| Tirzepatide (Mounjaro, Zepbound) | About 5 days45 | Once a week |
| Dulaglutide (Trulicity) | About 5 days8 | Once a week |
| Semaglutide (Ozempic, Wegovy) | About 1 week; present for about 5 weeks after the last shot1 | Once a week |
Try it
How Tirzepatide builds up
An estimate from a half-life of about 5 days, one dose a week for four weeks. The shape of the level, not a measurement.
Half-life is one input, not the answer: the weekly shots are the ones with milk data. If another pregnancy is possible, the stop-before dates and the birth-control pill rules are in our guide to GLP-1s and pregnancy. One rule carries into breastfeeding: tirzepatide and Foundayo can make birth-control pills less reliable, and their labels say to switch to a non-pill method or add condoms for 4 weeks (Foundayo: 30 days) after starting and after each dose increase4510.
What should you ask your prescriber and your baby's doctor?
- Is my baby old enough and big enough, given ACOG's advice on newborns and preterm babies?
- Which drug and form, a shot rather than a pill, fits what I take it for: diabetes, weight or both?
- Should I start lower or step up more slowly while I nurse, to protect what I eat?
- Who weighs the baby, and how often, while I am on it?
- If I take a birth-control pill, what do I use for the weeks after each step-up?
For the first months on a dose, what to eat and how to keep protein up is in our guide to what to eat on a GLP-1.
Sources
- Novo Nordisk. OZEMPIC (semaglutide) injection, prescribing information (DailyMed, setid adec4fd2, SPL version 20, effective Jun 1, 2026): sections 8.2, 11 and 12.3. dailymed.nlm.nih.gov
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information (DailyMed, setid ee06186f, SPL version 19, revised 06/2026): section 8.2. dailymed.nlm.nih.gov
- Novo Nordisk. RYBELSUS and OZEMPIC (oral semaglutide) tablets, prescribing information (DailyMed, setid 27f15fac, SPL version 14, revised 1/2026): section 8.2. dailymed.nlm.nih.gov
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, prescribing information (DailyMed, setid d2d7da5d, SPL version 40, effective Aug 27, 2026): sections 7.2, 8.2, 8.3, 11 and 12.3. dailymed.nlm.nih.gov
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information (DailyMed, setid 487cd7e7, SPL version 40, revised 08/2026): sections 8.2, 8.3 and 12.3. dailymed.nlm.nih.gov
- Novo Nordisk. SAXENDA (liraglutide) injection, prescribing information (DailyMed, setid 3946d389, SPL version 22, revised 02/2026): sections 8.2, 11 and 12.3. dailymed.nlm.nih.gov
- Novo Nordisk. VICTOZA (liraglutide) injection, prescribing information (DailyMed, setid 5a9ef4ea, SPL version 31, effective Oct 14, 2025): sections 8.2 and 12.3. dailymed.nlm.nih.gov
- Eli Lilly and Company. TRULICITY (dulaglutide) injection, prescribing information (DailyMed, setid 463050bd, SPL version 62, effective Jun 16, 2026): sections 8.2, 11 and 12.3. dailymed.nlm.nih.gov
- AstraZeneca. BYETTA (exenatide) injection, prescribing information (DailyMed, setid 53d03c03, SPL version 26, effective Sep 2, 2025): sections 8.2, 11 and 12.3. dailymed.nlm.nih.gov
- Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, prescribing information (DailyMed, setid 8ac446c5, SPL version 10, effective Jul 29, 2026): sections 8.2, 8.3, 11 and 12.3. dailymed.nlm.nih.gov
- Diab H, Fuquay T, Datta P, Bickel U, Thompson J, Krutsch K. Subcutaneous semaglutide during breastfeeding: infant safety regarding drug transfer into human milk. Nutrients. 2024;16(17):2886. PubMed 39275201
- Drugs and Lactation Database (LactMed). Semaglutide. National Institute of Child Health and Human Development; updated Aug 15, 2026. PubMed 30000039
- Drugs and Lactation Database (LactMed). Tirzepatide. National Institute of Child Health and Human Development; updated Aug 15, 2026. PubMed 35759552
- Drugs and Lactation Database (LactMed). Liraglutide. National Institute of Child Health and Human Development; updated Aug 15, 2026. PubMed 30000036
- American College of Obstetricians and Gynecologists. Use of glucagon-like peptide-1 receptor agonists in pregnancy and lactation. Practice Advisory, October 2026. acog.org
- European Medicines Agency. Ozempic: EPAR product information (summary of product characteristics), section 4.6. Read Nov 20, 2026. ema.europa.eu
- European Medicines Agency. Wegovy: EPAR product information (summary of product characteristics), section 4.6. Read Nov 20, 2026. ema.europa.eu
- European Medicines Agency. Mounjaro: EPAR product information (summary of product characteristics), section 4.6. Read Nov 20, 2026. ema.europa.eu
- Medicines and Healthcare products Regulatory Agency. GLP-1 medicines for weight loss and diabetes: what you need to know. GOV.UK, updated Feb 5, 2026. gov.uk
- Richardson K, Kiptoo J, Mpora Odongkara B, Ojara FW, Waitt C. Maternal-to-infant transfer of medications for type 2 diabetes mellitus via breastmilk: a systematic review of available evidence and clinical guidelines. Clin Pharmacol Ther. 2026;119(5):1223-1234. PubMed 41670332
- US Food and Drug Administration. Drugs@FDA (openFDA): BYETTA (NDA021773), BYDUREON (NDA022200), BYDUREON BCISE (NDA209210) and exenatide (ANDA206697), marketing status Discontinued. Read Nov 20, 2026. accessdata.fda.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.